Sirtris Satisfies GSK's M&A Appetite
Executive Summary
Pathway-oriented platforms are rare, and dealmaking around them can be complicated: partner too early or for too little and you risk giving away the store. But Sirtris pulled it off, via M&A, when GSK tendered a whopping $720 million for it in April. The deal is another example of Pharma's interest in platform biotechs and its hunger for innovation. But the unique nature of Sirtris's platform -- broad, but around a single set of biological targets -- makes it more one-off than trend-setting.
You may also be interested in...
Discredited SIRT1 Stops DNA Damage In Neurons
SIRT1, the molecule activated by the controversial anti-aging supplement resveratrol, has been among the most disappointing of drug targets but now, research has linked it, along with the enzyme HDAC1, to the ability to stabilize the genome following DNA damage. The work is encouraging for the development of activators of SIRT1 and HDAC1 as neuroprotectants and DNA repair agents.
Financings Of The Fortnight Follows OvaScience’s Unique Route To Going Public
Plus news on recent financial activity by Stem Cells Inc., Sanofi, Avalon Ventures and Aerpio Therapeutics.
The Allure Of High-Hanging Fruit: Why VCs and Biotech Execs See Value In Difficult Drug Targets
An agile and energetic cohort of biotech platform companies plans to capture Big Pharma's imagination--and its pocketbook--by going after intractable drug targets that have long eluded the industry, and they're doing it on a shoestring budget.